Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

Moderna Expects To Ship 20 Million Corona Virus Vaccines By The End Of The Year

A Dark Winter? Sounds Like Fake News to Me!


GREAT News Folks!

The Biotech Firm Moderna has just announced that it expects to ship 20 million vaccines by the end of this year! 

This is the complete opposite of the doom and gloom that democrats just cant stop peddling!

As usual though folks we here at WeLoveTrump are here to bring you THE FACTS! 

Check it out! 

Our freinds at Fox News had more on the story: 

Biotech firm Moderna expects to have about 20 million doses of its experimental coronavirus vaccine ready to ship in the U.S. by the end of the year.

The Massachusetts-based drug developer will be prepared to distribute the vaccine, dubbed mRNA-1273, around the country if its late-stage clinical study proves that it works and the feds approve it, according to company officials.

“From a distribution standpoint, we’re ready,” Dr. Tal Zaks, Moderna’s chief medical officer, told investors on a Thursday conference call. “We expect mRNA-1273 to be distributed within existing infrastructure. There’s nothing new required that hasn’t already been used for years with many other vaccines.”

Moderna said it’s “actively preparing” for the launch of its vaccine, which is one of four going through Phase 3 clinical trials in the U.S. The company has enrolled 30,000 people in the study and has said it could have enough data to seek emergency approval for the shot by the end of November.

CNBC also had this to say: 

Moderna is prepping for the global launch of its potential coronavirus vaccine, already taking in $1.1 billion in deposits from governments awaiting the potentially lifesaving drug, the biotech firm said Thursday in its third-quarter earnings report.

The Cambridge, Massachusetts-based company said it was in ongoing talks with the World Health Organization-backed COVAX initiative on a tiered pricing proposal for its potential vaccine, which it’s tentatively calling mRNA-1273. It already has supply agreements in North America, the Middle East and in other regions of the world.Just over half, 53%, of the participants in the trial are male and 47% are female, according to a presentation from the company. The vast majority of participants are over the age of 25, with only 5% in the 18 to-24 age group.


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here.

I post all day long over in Telegram.

If we’re not already connected, please follow me over there.

I’ll see you there!

We Love Trump
Thanks for sharing!